Sugi Predict

Sugi Predict / Compounds / SCHEMBL141481

SCHEMBL141481

SCHEMBL141481

COC(=O)c1ccc(-c2nc(-c3ccc(OC)c(F)c3)cc(C(=O)OC)c2N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 1/20 0.48
▸ MEN1 O00255 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ NEK2 P51955 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ PLA2G2A P14555 2/20 0.43
▸ JAK2 O60674 3/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ AR P10275 1/20 0.41
▸ MAP2K4 P45985 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111145 0.91 DHODH (0.48) DHODHMEN1ALDH1A1KMT2ARAB9A
SCHEMBL15976449 0.82 DHODH (0.41) DHODHMEN1ALDH1A1KMT2ARAB9A
SCHEMBL140353 0.78 PLA2G2A (0.64) MEN1ALDH1A1KMT2ARAB9ASMN1; SMN2
SCHEMBL139223 0.75 MAPT (0.47) MEN1ALDH1A1KMT2ARAB9ASMN1; SMN2
SCHEMBL146426 0.74 JAK2 (0.59) DHODHALDH1A1LMNAHTTJAK2
SCHEMBL22981957 0.74 DHODH (0.47) DHODHMEN1ALDH1A1KMT2ARAB9A
SCHEMBL29707061 0.74 DHODH (0.47) DHODHMEN1ALDH1A1KMT2ARAB9A
SCHEMBL110884 0.74 PLA2G2A (0.59) DHODHMEN1ALDH1A1KMT2AMAPT
SCHEMBL15976010 0.74 DHODH (0.41) DHODHMEN1ALDH1A1KMT2ARAB9A
SCHEMBL13276414 0.73 AR (0.57) KMT2ARAB9ALMNAMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 — — EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 — — EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 DHODH 3348/4885MEN1 2279/4885ALDH1A1 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.